Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 40 | AmgenINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07581184 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer(BActinium-1) | recruiting | Phase 1 | 138 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07610083 | A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer | not yet recruiting | — | 376 | IRCCS San RaffaeleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07649122 | This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer. | recruiting | Phase 3 | 232 | Norroy Bioscience Co., LTDINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07690306 | Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT | enrolling by invitation | — | 1,500 | Xiangya Hospital of Central South UniversityOTHER | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07807202 | Improving HPV Vaccination Coverage Among Adolescent Girls in Mali and Côte d'Ivoire Through Community Health Worker Follow-up | active not recruiting | N/A | 17,188 | Arsène Brunelle SandieOTHER | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07819760 | Radical Prostatectomy Without Prior Biopsy | not yet recruiting | N/A | 10 | Botkin HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer(SWIFT) | not yet recruiting | Phase 2 | 48 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820566 | Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)(3DBlood) | recruiting | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00525720 | Brachytherapy for Prostatic Carcinoma Patients | active not recruiting | Phase 2 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00769223 | Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer | active not recruiting | — | 3,561 | University of California, San FranciscoOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00791635 | Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer | active not recruiting | — | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01012817 | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | active not recruiting | Phase 1 / Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02703623 | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 196 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | active not recruiting | Phase 2 / Phase 3 | 612 | NRG OncologyOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04723095 | Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix(NeCTuR) | recruiting | — | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04905069 | Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer(SABRE) | active not recruiting | N/A | 500 | Boston Scientific CorporationINDUSTRY | 9 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06111781 | The SUGAR Study; SBRT and Relugolix) for Prostate Cancer | recruiting | Phase 2 | 60 | Yale UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC(NAPISTAR1-01) | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06451614 | SpaceIT Hydrogel System for Perirectal Spacing(HYDROSPACE) | active not recruiting | N/A | 230 | Boston Scientific CorporationINDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06511141 | Sacral Neuromodulation for Male Overactive Bladder (MOAB) | recruiting | N/A | 150 | Axonics, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06674811 | Biomarkers of Resiliency In Childhood Cancer Surgery(BRICCS) | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 297 | Regeneron PharmaceuticalsINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06908694 | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy(GAINPCCONTROL) | active not recruiting | Phase 4 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07098182 | Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique) | recruiting | N/A | 50 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07539844 | Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries(ConFeR) | recruiting | — | 1,000 | AbbVieINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07772869 | Uterine Lavage to Detect Ovarian Cancer Risk | recruiting | N/A | 75 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07808359 | Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma(APOLO) | not yet recruiting | Phase 2 | 58 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818395 | Spatial Multi-Omics of Perineural Invasion Microenvironment and Prognosis in Prostate Cancer | not yet recruiting | — | 120 | Anhui Medical UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818421 | Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer | not yet recruiting | — | 100 | Anhui Medical UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00588185 | [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer | recruiting | N/A | 300 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01617161 | Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer(PARTIQoL) | active not recruiting | N/A | 454 | Massachusetts General HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02960022 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | active not recruiting | Phase 2 | 900 | Astellas Pharma Global Development, Inc.INDUSTRY | 38 | Sep 11, 2026 | clinicaltrials |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04689828 | 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer(PSMAfore) | active not recruiting | Phase 3 | 469 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 11, 2026 | clinicaltrials |
| NCT04905082 | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | active not recruiting | N/A | 465 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe) | active not recruiting | Phase 1 / Phase 2 | 320 | Ascendis Pharma Oncology Division A/SINDUSTRY | 10 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05849298 | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC(PSMACare) | active not recruiting | Phase 2 | 49 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT05979493 | QL Block in Laparoscopic Myomectomy | recruiting | Phase 4 | 80 | Joseph Findley MDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05983198 | Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT(SatisfACtion) | active not recruiting | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy(CLARIFY) | recruiting | Phase 3 | 383 | Clarity Pharmaceuticals LtdINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials